NZ581332A - Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture - Google Patents

Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture

Info

Publication number
NZ581332A
NZ581332A NZ581332A NZ58133208A NZ581332A NZ 581332 A NZ581332 A NZ 581332A NZ 581332 A NZ581332 A NZ 581332A NZ 58133208 A NZ58133208 A NZ 58133208A NZ 581332 A NZ581332 A NZ 581332A
Authority
NZ
New Zealand
Prior art keywords
seq
replikin
shrimp
vaccine
synthetic
Prior art date
Application number
NZ581332A
Other languages
English (en)
Inventor
Samuel Bogoch
Elenore S Bogoch
Samuel Winston Bogoch
Anne Elenore Borsanyi
Original Assignee
Samuel Bogoch
Elenore S Bogoch
Samuel Winston Bogoch
Anne Elenore Borsanyi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/755,597 external-priority patent/US20080260764A1/en
Priority claimed from US11/923,559 external-priority patent/US8050871B2/en
Priority claimed from US12/010,027 external-priority patent/US20090017052A1/en
Application filed by Samuel Bogoch, Elenore S Bogoch, Samuel Winston Bogoch, Anne Elenore Borsanyi filed Critical Samuel Bogoch
Publication of NZ581332A publication Critical patent/NZ581332A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/18011—Nimaviridae
    • C12N2710/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/22011—Dicistroviridae
    • C12N2770/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
NZ581332A 2007-05-30 2008-04-23 Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture NZ581332A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US11/755,597 US20080260764A1 (en) 2006-05-30 2007-05-30 Replikin peptides and uses thereof
US95474307P 2007-08-08 2007-08-08
US93549907P 2007-08-16 2007-08-16
US93581607P 2007-08-31 2007-08-31
US98233607P 2007-10-24 2007-10-24
US98233307P 2007-10-24 2007-10-24
US98233807P 2007-10-24 2007-10-24
US11/923,559 US8050871B2 (en) 2006-10-24 2007-10-24 Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
US99167607P 2007-11-30 2007-11-30
US12/010,027 US20090017052A1 (en) 2007-01-18 2008-01-18 Methods of determining lethality of pathogens and malignancies involving replikin peak genes
PCT/US2008/061336 WO2008156914A2 (en) 2007-05-30 2008-04-23 Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture

Publications (1)

Publication Number Publication Date
NZ581332A true NZ581332A (en) 2012-06-29

Family

ID=40346767

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ581332A NZ581332A (en) 2007-05-30 2008-04-23 Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture

Country Status (11)

Country Link
US (1) US9408902B2 (https=)
EP (2) EP2167122A2 (https=)
JP (1) JP5675348B2 (https=)
KR (1) KR20100006574A (https=)
CN (1) CN101969993B (https=)
AU (1) AU2008266702A1 (https=)
CA (1) CA2689181A1 (https=)
IL (1) IL202296A0 (https=)
MX (1) MX2009013091A (https=)
NZ (1) NZ581332A (https=)
WO (1) WO2008156914A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8050871B2 (en) * 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
US20090017052A1 (en) * 2007-01-18 2009-01-15 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
JP5675348B2 (ja) 2007-05-30 2015-02-25 ボゴーク，サミュエル 水産養殖における無脊椎動物の病原性感染に対する合成レプリキンペプチド
US20090269367A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US20100144589A1 (en) * 2008-08-08 2010-06-10 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
KR101119445B1 (ko) 2009-10-20 2012-03-13 완도군 알긴산과 울금을 이용한 넙치사료 제조방법
WO2013013075A2 (en) 2011-07-20 2013-01-24 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
US20130243803A1 (en) 2012-03-09 2013-09-19 Samuel Bogoch Therapies, vaccines, and predictive methods for infectious salmon anemia virus
CN104387451B (zh) * 2014-11-07 2020-12-18 浙江海洋学院 一种对非酒精性脂肪肝病细胞模型具有修复作用的文蛤酶解寡肽及其制备方法
CN112741030B (zh) * 2019-10-31 2022-08-30 广东海洋大学 一种饵料培育方法
CN115669584B (zh) * 2022-09-28 2024-04-23 中国海洋大学 一种基于攻击性性状对三疣梭子蟹进行亲本选育的方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132769A (en) * 1974-10-30 1979-01-02 Osther Kurt B Cancer antigen, cancer therapy, and cancer diagnosis
IE56509B1 (en) 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
EP0221748A3 (en) * 1985-11-01 1988-10-12 Samuel Dr. Bogoch A process for the production of human antibodies
DE3628658A1 (de) 1986-08-23 1988-03-03 Boehringer Ingelheim Int Polypeptide des rhinovirusstammes hrv89 sowie die hierfuer codierenden dna-molekuele
EP0400076B1 (en) 1988-01-26 1996-05-15 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce A synthetic antigen evoking anti-hiv response
US5104854A (en) * 1989-02-01 1992-04-14 Washington University Antiviral peptides
JPH0321867A (ja) 1989-06-20 1991-01-30 Daido Steel Co Ltd 金属中のガス成分を分析する方法および装置
US5280113A (en) * 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5231167A (en) * 1989-09-08 1993-07-27 The Regents Of The University Of California Immunoglobulin-binding polypeptides
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
US20050271676A1 (en) * 1993-03-05 2005-12-08 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6242578B1 (en) 1994-02-17 2001-06-05 Samuel Bogoch Aglyco products and methods of use
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
WO1996032106A1 (en) 1995-04-11 1996-10-17 Samuel Bogoch Aglyco products
JPH08287088A (ja) 1995-04-17 1996-11-01 Canon Inc 情報検索方法及びその装置
CA2216645A1 (en) 1995-04-25 1996-11-21 Irori Remotely programmable matrices with memories and uses thereof
US6023659A (en) * 1996-10-10 2000-02-08 Incyte Pharmaceuticals, Inc. Database system employing protein function hierarchies for viewing biomolecular sequence data
JPH10212300A (ja) 1996-11-26 1998-08-11 Sankyo Co Ltd ペプチドワクチン
JPH111493A (ja) 1997-06-12 1999-01-06 Kuraray Co Ltd ペプチドおよびこれを固定化してなる医療材料
US6070126A (en) * 1997-06-13 2000-05-30 William J. Kokolus Immunobiologically-active linear peptides and method of identification
JPH11232291A (ja) * 1998-02-16 1999-08-27 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質立体構造データベース検索方法
IT1300059B1 (it) 1998-04-24 2000-04-05 Ist Naz Ric Sul Cancro Peptidi ad attivita' chemiotattica e anti-hiv
US7176275B2 (en) * 1998-09-04 2007-02-13 Samuel Bogoch Anthrax and small pox replikins and methods of use
IL144559A0 (en) 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis
JP2000253876A (ja) 1999-03-08 2000-09-19 Dnavec Research Inc センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
US6175830B1 (en) * 1999-05-20 2001-01-16 Evresearch, Ltd. Information management, retrieval and display system and associated method
WO2001004135A2 (en) 1999-07-13 2001-01-18 The Regents Of The University Of Michigan Crosslinked dna condensate compositions and gene delivery methods
US6470277B1 (en) * 1999-07-30 2002-10-22 Agy Therapeutics, Inc. Techniques for facilitating identification of candidate genes
US7189800B2 (en) 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
KR100906102B1 (ko) * 2001-03-27 2009-07-07 사무엘 보고치 레플리킨 펩타이드 및 그의 이용
US7894999B2 (en) * 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
EP1419175B1 (en) 2001-03-27 2011-04-27 Samuel Dr. Bogoch Replikin peptides and uses thereof
US7774144B2 (en) 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
JP2006500001A (ja) 2001-07-09 2006-01-05 ボゴーク，サミュエル レプリキンペプチドとその使用
JP4047053B2 (ja) * 2002-04-16 2008-02-13 富士通株式会社 繰り返しを含む順序パターンを用いた検索装置および方法
WO2004085455A1 (en) * 2003-03-24 2004-10-07 The University Of Hong Kong A diagnostic assay for the human virus causing severe acute respiratory syndrome (sars)
US8494781B2 (en) 2003-06-06 2013-07-23 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US20050021134A1 (en) 2003-06-30 2005-01-27 Opie John C. Method of rendering a mechanical heart valve non-thrombogenic with an electrical device
WO2005012337A2 (en) 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
WO2006088962A2 (en) 2005-02-16 2006-08-24 Samuel Bogoch Replikin peptides and uses thereof
US20070178115A1 (en) 2005-08-15 2007-08-02 Tang De-Chu C Immunization of avians by administration of non-replicating vectored vaccines
AR060565A1 (es) 2006-04-21 2008-06-25 Dow Agrosciences Llc Vacuna para la gripe aviaria y metodos de uso
KR20090016671A (ko) * 2006-05-30 2009-02-17 사무엘 보고치 레플리킨 펩티드 및 이의 용도
AU2007261196A1 (en) 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
WO2008073161A2 (en) * 2006-08-14 2008-06-19 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US8050871B2 (en) * 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
US20090017052A1 (en) * 2007-01-18 2009-01-15 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
US20080241188A1 (en) 2007-03-30 2008-10-02 Zeon Corporation Turkey herpesvirus vectored recombinant containing avian influenza genes
JP5675348B2 (ja) 2007-05-30 2015-02-25 ボゴーク，サミュエル 水産養殖における無脊椎動物の病原性感染に対する合成レプリキンペプチド

Also Published As

Publication number Publication date
US9408902B2 (en) 2016-08-09
US20090041795A1 (en) 2009-02-12
JP5675348B2 (ja) 2015-02-25
IL202296A0 (en) 2011-08-01
CA2689181A1 (en) 2008-12-24
MX2009013091A (es) 2010-07-30
CN101969993A (zh) 2011-02-09
KR20100006574A (ko) 2010-01-19
CN101969993B (zh) 2013-10-16
JP2010528610A (ja) 2010-08-26
WO2008156914A2 (en) 2008-12-24
EP2594578A1 (en) 2013-05-22
WO2008156914A3 (en) 2009-03-19
AU2008266702A1 (en) 2008-12-24
EP2167122A2 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
NZ581332A (en) Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
Rout et al. DNA vaccines encoding viral envelope proteins confer protective immunity against WSSV in black tiger shrimp
Musthaq et al. Localization of VP28 on the baculovirus envelope and its immunogenicity against white spot syndrome virus in Penaeus monodon
Ramos-Carreño et al. Antiviral therapy in shrimp through plant virus VLP containing VP28 dsRNA against WSSV
WO2008140557A2 (en) A method of predicting influenza outbreaks
JP3780256B2 (ja) 小エビ白斑病症候群（ＷｈｉｔｅＳｐｏｔＳｙｎｄｒｏｍｅ）ウイルスの抗原性蛋白質及びその使用
IL266234B1 (en) Novel tilapia virus and uses thereof
Einer-Jensen et al. Dual DNA vaccination of rainbow trout (Oncorhynchus mykiss) against two different rhabdoviruses, VHSV and IHNV, induces specific divalent protection
Mukherjee et al. Omicron variant infection and the associated immunological scenario
JP5132780B2 (ja) 水産用サブユニットワクチン
Ma et al. Screening the potential part of the G protein antigen is an achievable strategy to improve the immune effect of DNA vaccine against MSRV infection
Mekata Strategy for understanding the biological defense mechanism involved in immune priming in kuruma shrimp
Chen et al. Development and evaluation of nucleoprotein-based rapid detection test for Siniperca chuatsi rhabdovirus
Jaranathummakul et al. Multivalent display of VP28 on chimeric virus-like particles enhances binding to shrimp target tissues: A novel antiviral strategy against white spot syndrome virus
JP2008063302A (ja) クルマエビ属ホワイトスポット病用経口ワクチン
Li et al. Combined amino acid mutations in position 67 and 438 in the glycoprotein of infectious hematopoietic necrosis virus can further reduce the pathogenicity
WO2009138752A2 (en) Fish vaccine
WO2002083725A1 (en) Novel stress protein with chaperone activity
Akhila et al. Protection of Litopenaeus vannamei against White Spot Syndrome Virus using bacterially expressed recombinant envelope proteins VP39 and VP28
Ngo et al. Study on the pathogenesis of the white spot syndrome virus (WSSV) on juvenile Penaeus monodon in Vietnam
CN107827954A (zh) Vp53b和vp110抗体及其在制备防治对虾白斑综合征的药物中的应用
Brown et al. Oral avian influenza vaccine
WO2002079231A2 (en) Nucleic acids encoding isav polypeptides
Wang et al. Collaboration between a Soluble C-Type
CN113663063A (zh) 登革病毒的修饰性mRNA疫苗

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed